Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Table 1 Patient and treatment characteristics (N = 159 patients)

Baseline characteristics
Age, years	59.0	30–81
Age group, years
< 50	38	23.9%
50 to < 60	44	27.5%
60 to < 70	46	28.8%
≥ 70	31	19.4%
Race
Non-Hispanic white	80	50.3%
Hispanic	40	25.2%
African-American	17	10.7%
Asian	15	9.4%
Others	6	3.8%
Missing data	1	0.6%
Breast cancer stage
I	34	21.4%
II	88	55.3%
III	37	23.3%
ER, PR, HER2 status
ER+ or PR+, HER2-	106	66.7%
HER2+	25	15.7%
ER-PR-HER2-	28	17.6%
Type of chemotherapy
Neoadjuvant	17	10.7%
Adjuvant	142	89.3%
Chemotherapy regimen
AC-T	56	35.2%
TC	59	37.1%
AC-TH	11	6.9%
TCH	11	6.9%
Sequential A-T-C	10	6.3%
Other non-HER2-targeted therapy	6	3.8%
Other HER-2-targeted therapy	6	3.8%
Anthracycline-containing regimen
No	75	47.2%
Yes	84	52.8%
Comorbidities
Hypertension	54	34.0%
Arthritis	47	29.6%
Depression	31	19.5%
Circulation problem	22	13.8%
Other cancers	18	11.3%
Stomach disorders	17	10.7%
Other^a
Number of comorbidities ≥ 1	105	66.0%
Number of comorbidities ≥ 2	64	40.3%
Number of comorbidities ≥ 3	35	22.0%

Values are presented as median and range, or number and percentage
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, TC docetaxel plus cyclophosphamide, AC-T doxorubicin plus cyclophosphamide followed by paclitaxel, TCH docetaxel, carboplatin and trastuzumab, AC-TH doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab, A-T-C sequential doxorubicin, paclitaxel and cyclophosphamide
^aOther: heart disease (N = 15, 9.4%); diabetes mellitus (N =12, 7.5%); glaucoma (N = 9, 5.7%); emphysema (N = 5, 3.1%); liver/kidney disease (N = 2, 1.3%); stroke (N = 1, 0.6%)

ISSN: 1465-542X